Oncomatryx has raised $67 million to support the clinical development of its next-generation antibody-drug conjugates, known as Quantum ADCs, targeting the tumor microenvironment in metastatic solid tumors.
The financing round was backed by a mix of public and private investors. This included a $28 million strategic investment from the Spanish government through Centro para el Desarrollo Tecnológico e Innovación, $18 million from Kutxa Fundazioa, $12 million from the Basque Government alongside Ekarpen VC, and $2 million from BBK, in addition to other Spanish and international private investors.
The funding will be used to advance the company’s pipeline, including its lead candidate OMTX705 and additional Quantum ADC programs such as OMTX105, into clinical trials. The company is focused on targeting Cancer-Associated Fibroblasts within the tumor microenvironment, a strategy designed to improve treatment outcomes in metastatic cancers.
Oncomatryx combines artificial intelligence and quantum computing tools to design and optimize its ADC candidates. Its platform includes proprietary payloads, dual payload approaches, and specialized conjugation chemistry, supported by a developing fill-and-finish manufacturing facility in San Sebastián.
The company is also progressing clinical validation efforts. Phase Ib-II results for OMTX705, which targets Fibroblast Activation Protein in Cancer-Associated Fibroblasts, are expected to be presented at major oncology conferences throughout 2026.
This latest raise underscores growing institutional confidence in Oncomatryx’s approach and highlights continued public-private collaboration in advancing biotechnology innovation in Spain.
KEY QUOTES:
“We are thrilled to count on the continued support of our existing investors. This funding validates the clinical progress of our lead candidate OMTX705 and equips us to take OMTX105 and other Quantum ADCs into clinical trials.”
Dr. Laureano Simon, CEO of Oncomatryx
“This operation is an example of the public-private collaboration model that the Spanish Government promotes to strengthen our science and innovation system. Backing Oncomatryx means backing more advanced oncology therapies and positioning Spain at the forefront of biotechnology in the service of health.”
Diana Morant, Minister of Science, Innovation and Universities of the Spanish Government
“This investment is fully aligned with our objectives of fostering innovation and competitiveness, reinforcing our commitment to transformative projects with a tangible impact on our ecosystem.”
Eluska Sukia, Head of Investments at Kutxa Fundazioa
“With this investment, we are reinforcing our commitment to building a highly specialised biotechnology sector, which we consider strategic for the competitiveness and diversification of the Basque industrial base.”
Mikel Jauregi, Minister of Industry, Energy Transition and Sustainability of the Basque Government
